AI-generated summary
The authors studied mice with an APOE model of cholesterol dysregulation that were exposed to 808-nm near-infrared light for 1 hour daily over 3 months. They report that this light therapy reduced amyloid-β load by nearly half and normalized membrane lipid order, lipid rafts and cholesterol-related gene activity. The study was conducted in mice, so the findings may not apply directly to people with Alzheimer's disease.
- Who or what was studied
- Mice in an APOE transgenic model of cholesterol dysregulation and Alzheimer's disease
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The study was conducted in transgenic mice, not humans, so the results may not translate to patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Near-infrared, Transcranial photobiomodulation, Photobiomodulation therapy, Light-emitting diode, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.